Peptide YY (PYY)3–36 modulates thyrotropin secretion in rats

Oliveira, Karen Jesus; Paula, Gabriela Silva Monteiro de; Costa-e-Sousa, Ricardo H.; Souza, Luana Lopes; Moraes, Débora Cristina de; Curty, F. H.; Pazos‐Moura, Carmen C.

doi:10.1677/joe.1.06784

Cited by 12 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings imply that PYY may have long‐term benefits to reduce excess adiposity and ameliorate metabolic abnormalities associated with obesity through mechanisms independent of effects on food intake, notably stimulation of thyroid function. In keeping with this, PYY3‐36 injection was shown to increase serum levels of thyrotropin in fasted rats (Oliveira et al ., 2006).…”

Section: The Y2 Receptor (Table 2)mentioning

confidence: 65%

NPY receptors as potential targets for anti‐obesity drug development

Yulyaningsih

Zhang

Herzog

et al. 2011

British J Pharmacology

117

113

View full text Add to dashboard Cite

The neuropeptide Y system has proven to be one of the most important regulators of feeding behaviour and energy homeostasis, thus presenting great potential as a therapeutic target for the treatment of disorders such as obesity and at the other extreme, anorexia. Due to the initial lack of pharmacological tools that are active in vivo, functions of the different Y receptors have been mainly studied in knockout and transgenic mouse models. However, over recent years various Y receptor selective peptidic and non-peptidic agonists and antagonists have been developed and tested. Their therapeutic potential in relation to treating obesity and other disorders of energy homeostasis is discussed in this review. AbbreviationsARC, arcuate nucleus; d.d

show abstract

Section: The Y2 Receptor (Table 2)mentioning

confidence: 65%

NPY receptors as potential targets for anti‐obesity drug development

Yulyaningsih

Zhang

Herzog

et al. 2011

British J Pharmacology

117

113

View full text Add to dashboard Cite

show abstract

“…These findings suggest that PYY may have a longterm benefit to reduce excess adiposity and ameliorate metabolic abnormalities associated with obesity through mechanisms independent of effects on food intake, notably stimulation of thyroid function. In keeping with this, PYY3-36 injection was recently shown to increase serum levels of thyrotropin (thyroid-stimulating hormone) in fasted rats [72].…”

Section: Peptide Yy Knockout Mice and Peptide Yy Transgenic Micementioning

confidence: 68%

Y2, Y4 receptors and obesity

Lin

Zhang

Sainsbury

et al. 2007

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

The neuropeptide Y system -comprising neuropeptide Y, peptide YY, pancreatic polypeptide and the Y receptors through which they act (Y1, Y2, Y4, Y5 and y6) -has been at the center of attention with regards to regulation of feeding behavior and its possible involvement in obesity. In the past, research has focused mainly on the orexigenic and obesogenic action of this system, with Y1 and Y5 receptors being prime candidates as mediators of neuropeptide Y-induced hyperphagia and obesity. However, in recent years, the role of other members of the neuropeptide Y family, peptide YY, pancreatic polypeptide and the Y2 and Y4 receptors through which they predominantly act, have commanded increasing attention on account of their effects to mediate satiety and promote weight loss via actions in key brain structures, such as the arcuate nucleus of the hypothalamus and the brain stem. This review focuses on the role of peptide YY-and pancreatic polypeptide-like compounds as possible antiobesity drugs, taking into account their effects, not only on energy balance, but also in the regulation of bone formation, and highlights potential benefits of using Y2 and/or Y4 antagonists (as opposed to agonists such as peptide YY or pancreatic polypeptide) in the treatment of obesity.

show abstract

“…There have been only a few reports on the relationship between hypothyroxinemia and serum gut hormones, not only in children and infants, but also in adults. In fasting rats, PYY 3–36 at a dose of 3 or 30 μg/kg bodyweight elicited a significant rise in serum TSH observed 15 min after PYY 3–36 injection . It has also been reported that the fasting GLP‐1 level in pediatric human patients with overt hyperthyroidism was significantly increased .…”

Section: Discussionmentioning

confidence: 89%